Two Or More Nitrogen Atoms Bonded Directly To The Cyclohexyl Ring Patents (Class 514/36)
-
Publication number: 20120021038Abstract: A wound spacer device comprising multiple beads connected by non-absorbable suture material is disclosed. The device can be applied, for example, by a first responder to an injured individual, or can be applied by a trauma treatment facility, such as a Level 2 medical unit. In typical embodiments the device allows for site-specific controlled elution of an antimicrobial agent, such as Tobramycin, including defined elution over a period of time, such as 48 or 72 hours.Type: ApplicationFiled: September 23, 2011Publication date: January 26, 2012Applicant: Surmodics, Inc.Inventors: Tim M. Kloke, Steven J. Keough, Nathan Lockwood, Margaret R. Gardner, Robert W. Hergenrother, Ralph A. Chappa
-
Publication number: 20110288041Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: ApplicationFiled: April 7, 2011Publication date: November 24, 2011Applicant: Achaogen, Inc.Inventors: James Bradley Aggen, Martin Sheringham Linsell, Adam Aaron Goldblum, Darin James Hildebrandt, Timothy Robert Kane, Paola Dozzo, Micah James Gliedt, Heinz Ernst Moser
-
Publication number: 20110280824Abstract: The present disclosure provides copolymers including a first monomer including at least one phospholipid possessing at least one vinyl group and a second monomer including a furanone possessing vinyl and/or acrylate groups. Compositions, medical devices, and coatings including such copolymers are also provided.Type: ApplicationFiled: July 26, 2011Publication date: November 17, 2011Applicant: Tyco Healthcare Group LPInventor: Joshua B. Stopek
-
Publication number: 20110262459Abstract: Provided herein are compositions containing neamine, or a composition containing an agent that possesses one or more activities of neamine, and the research, diagnostic and therapeutic uses of such compounds, such as for the treatment of cancer.Type: ApplicationFiled: October 28, 2009Publication date: October 27, 2011Applicant: President and Fellows of Harvard CollegeInventor: Guofu Hu
-
Publication number: 20110218166Abstract: The present invention has as its objective to provide mucoadherent compositions with enhanced properties of bioadhesivity, consistency, stability and vaginal pH regulation. It can also be the carrier of an active principle for the treatment or prophylaxis of disturbances or diseases caused in mucosa, particularly in the vaginal tract, as well as their use.Type: ApplicationFiled: August 14, 2009Publication date: September 8, 2011Applicant: Incrementha PD&I - Pesquisa, Desenvolvimento e Inovecao de Famacos e Medicamentos Ltda.Inventors: Haline Fernanda Santana Castanho, Lupércio Calefe
-
Patent number: 7964589Abstract: Mixtures of at least two active principles, of which at least one is the sodium salt, are precipitated from an organic solution containing the same active principles in salified or non-salified acid form.Type: GrantFiled: July 27, 2006Date of Patent: June 21, 2011Assignee: ACS Dobfar S.p.A.Inventors: Maurizio Zenoni, Angelo Giovanni Cattaneo, Leonardo Marsili
-
Publication number: 20110118202Abstract: The dimerization of HIV RNA is a key step in the virus replication cycle. Based on RNA DIS crystal structures, a novel kind of compounds, dimeric or not, based on neamine was designed and synthesized. Biological studies showed that such compounds bind and interfere with the targeted RNA sequence, opening a new anti-HIV approach. The crystal structures and bio-chemical experiments showed that the DIS of HIV-1 genomic RNA is a target for new anti-HIV drugs and that those drugs could be derived from aminoglycosides. The results revealed that binding of aminoglycosides to the DIS is specific regarding both the aminoglycoside family and the RNA subtype.Type: ApplicationFiled: March 23, 2007Publication date: May 19, 2011Inventors: Patrick Pale, Jean-Marc Weibel, Anne Bodlenner, Roland Marquet, Jean-Cristophe Paillart, Philippe Dumas, Eric Ennifar, Philippe Walter
-
Patent number: 7939502Abstract: The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium Pseudomonas aeruginosa associated to lung diseases such as cystic fibrosis.Type: GrantFiled: December 18, 2009Date of Patent: May 10, 2011Assignee: Chiesi Farmaceutici S.p.A.Inventors: Chiara Malvolti, Raffaella Garzia
-
Patent number: 7915229Abstract: An aminocarboxylic acid chelating agent, preferably EDTA, or a salt thereof has been found to be useful for inhibiting particulate formation in piperacillin/tazobactam parenteral combinations. The composition may also contain a buffer, preferably citrate, and optionally an aminoglycoside. The product may be in the form of a frozen composition that can be thawed for use. The product may also be in the form of a cryodesiccated powder that can be reconstituted by addition of an aqueous vehicle to reform a solution.Type: GrantFiled: February 13, 2009Date of Patent: March 29, 2011Assignee: Wyeth Holdings CorporationInventors: Jonathan Marc Cohen, Syed Muzafar Shah, Christian Luther Ofslager, Mahdi Bakir Fawzi
-
Publication number: 20110015137Abstract: The present invention provides RecA inhibitors, compositions containing them, systems for identifying or characterizing them, and methods of using them.Type: ApplicationFiled: July 7, 2008Publication date: January 20, 2011Applicant: Trustees of Boston UniversityInventor: Guillaume Cottarel
-
Publication number: 20100323978Abstract: The present invention relates to a delivery system for ophthalmic drugs, and more particularly, to a non aqueous oil delivery system. Low concentrations of ophthalmic drugs suspended in an oil vehicle delivery system are as therapeutically effective in man and animals as the corresponding higher concentrations of ophthalmic drugs that are commercially used in aqueous solutions. Eye drops that utilize this nonaqueous oil delivery system, when used in man, are comfortable to use and produce little ocular irritation, have a longer shelf-life, low systemic toxic potential, and only short term blurring of vision. Using this nonaqueous oil delivery system, a single drop of ophthalmic drug with a concentration that is 10 times less than the same drug used in commercially available aqueous eye drops is as effective as the commercially available aqueous ophthalmic eye drops that require many applications to be effective.Type: ApplicationFiled: June 22, 2009Publication date: December 23, 2010Inventor: Calvin Hanna
-
Publication number: 20100311680Abstract: This invention concerns compounds with the formula: in which: R1=OH or NH2; OR2, OR3, OR4 and OR5 are alcohol, ether, ester, carbonate, carbamate, sulphonate or sulphamate groups; and if R5=H if R2=R3=R4, then R2, R3 and R4?H; if R2=H, then R3?H and R4?H; if R3=H, then R2?H and R4?H; if R4=H, then R2?H and R3?H; if R5?H if R2=H, then R3?H and R4?H; if R3=H, then R2?H and R4?H; if R4=H, then R2?H and R3?H, their use as antibiotic agents and the process for synthesising them.Type: ApplicationFiled: January 22, 2009Publication date: December 9, 2010Applicant: Universite Joseph FourierInventors: Jean-Luc Decout, Isabelle Baussane, Jerome Desire, Jean-Marc Paris
-
Publication number: 20100286031Abstract: An aqueous or powder composition includes anti-gram-negative antibiotic or salt thereof being present at an amount ranging from about 100 mg/ml to about 200 mg/ml. Another aqueous or powder composition includes anti-gram-positive antibiotic or salt thereof being present at a concentration ranging from about 0.6 to about 0.9 of the water solubility limit, at 25° C. and 1.0 atmosphere, of the anti-gram-positive antibiotic or salt thereof. Other embodiments include unit doses, kits, and methods.Type: ApplicationFiled: September 28, 2006Publication date: November 11, 2010Inventors: Chatan K. Charan, Sarvajna Dwivedi
-
Patent number: 7829543Abstract: Disclosed are methods of treating bacterial infections including those caused by multidrug resistant bacteria using polyamine efflux pump inhibiting compounds, including for example N-benzylated polyazaalkanes, N-benzylated polyaminoalkanes, or mixed N-benzylated poly(aza/amino)alkanes, optionally in combination with other drugs such as antibiotics, as well as pharmaceutical compositions thereof.Type: GrantFiled: January 7, 2004Date of Patent: November 9, 2010Assignee: Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Michael N. Alekshun
-
Publication number: 20100261646Abstract: Biodegradable polymeric microparticle compositions containing one or more active agents, especially those useful for treating or preventing or one or more diseases or disorders of the eye, and methods of making and using thereof, are described. The microsphere compositions release an effective amount of the one or more active agents for a period greater than 14 days in vivo, preferably greater than 60 days in vivo, more preferably up to 73 days in vivo, more preferably greater than 90 days in vivo, even more preferably over 100 days in vivo, and most preferably greater than 107 days in vivo. In a preferred embodiment, the microparticle compositions contain one or more active agents useful for managing elevated intraocular pressure (TOP) in the eye. In one embodiment, the microspheres are formed from polylactide-co-glycolide (“PLGA”); in another embodiment, the microspheres are formed from a blend PLGA and poly lactic acid (“PLA”).Type: ApplicationFiled: June 18, 2008Publication date: October 14, 2010Applicants: YALE UNIVERSITY, UNIVERISTY OF IOWA RESEARCH FOUNDATIONInventors: Erin Lavik, Young H. Kwon, Markus Kuehn, Sandeep Saluja, James Bertram, John Huang
-
Patent number: 7749971Abstract: The present invention provides a method of treating lysosomal storage diseases such as Hurler syndrome and Batten disease in individuals in need of such treatment, comprising the step of administering to said individuals a therapeutically effective dose of an aminoglycoside. In addition, this method may further comprise treating the individual with enzyme replacement therapy. Furthermore, the present invention provides method of pharmacologically suppressing premature stop mutations in an individual with these lysosomal storage diseases, comprising the step of administering to said individual a pharmacologically effective dose of an aminoglycoside.Type: GrantFiled: February 20, 2002Date of Patent: July 6, 2010Inventors: David M. Bedwell, Kim M. Keeling
-
Publication number: 20100167992Abstract: The present invention relates to polymers modified to increase their resorbability. In particular, the polymers of the invention have phenyl ester side chains which are good leaving groups and which thereby increase the resorption rate of the polymer relative to the same polymer, for example, bearing a comparable amount of an alkyl ester side chain. Such polymers are generally water insoluble, but when modified are able to solublize drugs and upon degradation and resorption, release those in a physiological environment in a controlled and/or sustained manner.Type: ApplicationFiled: December 18, 2009Publication date: July 1, 2010Inventors: Arthur Schwartz, Satish Pulapura, Sarita Nethula
-
Publication number: 20100160247Abstract: The present invention is directed to a process for preparing a 2,26,6-d4-morpholine derivative represented by Structural Formula (I): or a salt thereof.Type: ApplicationFiled: June 17, 2009Publication date: June 24, 2010Applicant: CoNCERT Pharmaceuticals, Inc.Inventors: Julie F. Liu, Xuejun Tang, Scott L. Harbeson, Craig E. Masse
-
Patent number: 7696178Abstract: The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium Pseudomonas aeruginosa associated to lung diseases such as cystic fibrosis.Type: GrantFiled: March 18, 2005Date of Patent: April 13, 2010Assignee: Chiesi Farmaceutici S.p.A.Inventors: Chiara Malvolti, Raffaella Garzia
-
Publication number: 20090318378Abstract: The invention relates to a new pharmaceutical composition, a method of treatment of infection and also a process to prepare the composition. The infectious complications are important causes of morbidity and mortality. Hospital acquired pneumonia (HAP) remains the most severe nosocomial infection in intensive care units. Beta-lactams alone are always considered inadequate when P. aeruginosa and/or methicillin-resistant S. aureus are implicated as pathogens or copathognes. The present invention provides the desired empirical therapy for control of all bacterial infections. The invention provides antibiotic combination products for delivering at least two different antibiotics, through parenteral dosage form comprising protein-synthesis-inhibiting antibiotic which is amikacin or its sulphate salt and non-protein-synthesis-inhibiting antibiotic which is cefepime or its hydrochloride salt. The invention provides a total solution, against multiresistant P. aeruginosa, or Acinetobacter spp.Type: ApplicationFiled: December 16, 2005Publication date: December 24, 2009Applicant: VENUS REMEDIES LIMITEDInventor: Manu Chaudhary
-
Publication number: 20090155326Abstract: The present invention is directed generally to a layered polymeric monofilament fiber drug delivery device, where each layer of the device can contain a different polymer, drug, additive, or any combination or mixture thereof. The layered nature of the current monofilament polymeric monofilament device provides the capability to modulate the release of one or more drugs and/or the mechanical properties of the fiber so that drug release and device failure can be separately tuned to provide for the tailored introduction of therapeutically effective drugs or agents to a target tissue. Moreover, the fiber may comprise more than one distinct segments along its length, each segment itself having different combinations and/or numbers of layers thereby providing even greater freedom in the design of the therapeutic delivery device. The invention is also directed to a method of manufacturing such a layered polymeric monofilament fiber drug delivery device, and methods of treatment using such devices.Type: ApplicationFiled: November 12, 2008Publication date: June 18, 2009Inventors: Brendan C. Mack, Mark E. Davis, Kenneth W. Wright
-
Publication number: 20090093422Abstract: This invention relates to novel N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide derivatives, their acceptable acid addition salts, solvates and hydrates. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by antimicrobial agents.Type: ApplicationFiled: June 17, 2008Publication date: April 9, 2009Inventors: Roger Tung, Scott Harbeson
-
Patent number: 7514404Abstract: The present invention relates to methods and compositions pertaining to conjugates composed of a peptide nucleic acid (PNA) moiety and a neamine derivative moiety. Methods for using such conjugates for modulating the activity of a target nucleic acid molecule and for preventing or treating a disease associated with an aberrant nucleic acid molecule are also provided.Type: GrantFiled: December 6, 2004Date of Patent: April 7, 2009Assignee: University of Medicine & Dentistry of New JerseyInventors: Jean-Luc Decout, Virendra N. Pandey, Emmanuel Riguet
-
Patent number: 7498312Abstract: An aminocarboxylic acid chelating agent, preferably EDTA, or a salt thereof has been found to be useful for inhibiting particulate formation in piperacillin/tazobactam parenteral combinations. The composition may also contain a buffer, preferably citrate, and optionally an aminoglycoside. The product may be in the form of a frozen composition that can be thawed for use. The product may also be in the form of a cryodesiccated powder that can be reconstituted by addition of an aqueous vehicle to reform a solution.Type: GrantFiled: April 7, 2004Date of Patent: March 3, 2009Assignee: Wyeth Holdings CorporationInventors: Jonathan Marc Cohen, Syed Muzafar Shah, Christian Luther Ofslager, Mahdi Bakir Fawzi
-
Publication number: 20080241257Abstract: Nanoparticles of a biodegradable polymer containing a hydrophilic, cationic drug, like streptomycin, and preparations containing the same, are disclosed. Pharmaceutical preparations containing the nanoparticles are administered, preferably orally, to individuals suffering from a disease or condition, and the nanoparticles release the drug, in vivo, to treat the disease or condition.Type: ApplicationFiled: March 31, 2008Publication date: October 2, 2008Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Carmen Popescu, Hayat Onyuksel
-
Patent number: 7371733Abstract: The invention relates to novel paranmycin compounds that have activity against gram positive and gram negative bacteria, preferably bacteria that are resistant to other antibiotics.Type: GrantFiled: March 20, 2006Date of Patent: May 13, 2008Assignee: Utah State UniversityInventor: Cheng-Wei Tom Chang
-
Patent number: 7345024Abstract: The invention relates to hardly soluble antiphlogistic salts and antiphlogistic-antibiotic pharmaceutical preparations and their use. The hardly water soluble antiphlogistic antibiotics salts have as their cationic component one of the antibiotics gentamicin, clindamycin, neomycin, streptomycin, tetracycline, doxicyline, oxytetracycline and rolitetracycline and as their anionic component one of the antiphlogistics ibuprofen, naproxen, indomethacin, dexamethasone-21-phosphate, dexamethasone-21-sulfate, triamcinolone-21-phosphate and triamcinolone-21-sulfate. The antiphlogistic antibiotics salts are used in pharmaceutical preparations as controlled-release antibiotic/antibiotics drugs.Type: GrantFiled: June 20, 2003Date of Patent: March 18, 2008Assignee: Heraeus Kulzer GmbH & Co. KGInventors: Sebastian Vogt, Matthias Schnabelrauch, Klaus-Dieter Kühn
-
Patent number: 7244712Abstract: The present invention relates to aminoglycoside compounds having antibiotic activity. Moreover, the present invention relates to L-aminoglycoside compounds and diastereomers thereof which posses antibiotic activity and are not susceptible to development of resistant bacterial strains. The present invention also relates to methods of treatment and pharmaceutical compositions that utilize or comprise one or more of aminoglycoside compounds provided by the invention.Type: GrantFiled: September 14, 2004Date of Patent: July 17, 2007Assignee: President and Fellows of Harvard CollegeInventor: Robert R. Rando
-
Patent number: 7241746Abstract: The present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of misoprostol and an effective amount of an antibiotic. A suitable antibiotic is selected from the group consisting of doxycycline, gentamicin, tobramicin, ciprofloxacin, clindamycin, clarithromycin, azithromycin and metronidazole. Preferred antibiotics are doxycycline and ciprofloxacin. More preferably, the antibiotic is doxycycline. In its second aspect, the present invention is directed to a method for treating periodontal disease in a mammalian patient comprising administering to a mammalian patient in need of such treatment a therapeutically effective amount of misoprostol and an effective amount of an antibiotic. Typically, the mammalian patient is a human.Type: GrantFiled: August 6, 2003Date of Patent: July 10, 2007Assignee: Regena Therapeutics, LCInventors: Frank Wingrove, Rex McKee
-
Patent number: 7220727Abstract: The present invention provides aminoglycosides and pharmaceutical compositions that include the aminoglycosides. The aminogylcosides are useful to treat or prevent infectious diseases (e.g., bacterial infections) in a mammal (e.g., human).Type: GrantFiled: November 1, 2001Date of Patent: May 22, 2007Assignee: Wayne State UniversityInventors: Jalal Haddad, Lakshmi Kotra, Shahriar Mobashery
-
Patent number: 7124634Abstract: A capacitance accelerometer includes a housing, and a plate fixed within the housing. A moveable plate is disposed in substantially parallel relation to the fixed plate and is coupled to the housing along at least an edge. The moveable plate and the fixed plate define a distance. The distance varies in response to acceleration forces acting upon the moveable plate, and wherein the moveable plate and the fixed plate generate a charge displacement capacitance signal. A transimpedance amplifier receives the charge displacement capacitance signal and generates a scaled voltage signal therefrom. An acceleration signal is generated from the scaled voltage signal.Type: GrantFiled: July 29, 2003Date of Patent: October 24, 2006Assignee: The Boeing CompanyInventors: Ray F. Campbell, Joan D. Wada
-
Patent number: 7094431Abstract: This invention pertains to therapeutic antibacterial/antifungal-wound healing compositions comprising a therapeutically effective amount of antibacterial agents and/or antifungal agents and/or wound healing composition alone. In one embodiment, the wound healing composition comprises (a) zinc oxide; (b) calcium channel blocker, and (c) fat-soluble vitamins admixed with antibacterial and antifungal agents. The therapeutic antibacterial/antifungal-wound healing compositions may be utilized in a wide variety of pharmaceutical products and administered orally or topically.Type: GrantFiled: September 30, 2003Date of Patent: August 22, 2006Inventor: Mickey L. Peshoff
-
Patent number: 6987094Abstract: The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium Pseudomonas aeruginosa associated to lung diseases such as cystic fibrosis.Type: GrantFiled: June 14, 2002Date of Patent: January 17, 2006Assignee: Chiesi Farmaceutici S.p.A.Inventors: Chiara Malvolti, Raffaella Garzia
-
Patent number: 6900184Abstract: The invention pertains to pharmaceutical compositions of Zosyn® piperacillin with tazobactam in the presence of a buffer, preferably citrate, a particulate formation inhibitor, preferably EDTA optionally an aminoglycoside which when frozen and thawed or lyophilized and reconstituted reform a solution which has decreased particulate formation.Type: GrantFiled: April 14, 2003Date of Patent: May 31, 2005Assignee: Wyeth Holdings CorporationInventors: Jonathan Marc Cohen, Syed M. Shah, Christian Luther Ofslager, Mahdi Fawzi
-
Patent number: 6858589Abstract: The invention provides a method of potentiating the activity of antibacterial agents that act on bacterial cell walls, comprising the step of administering to a subject an antibacterial agent and an aminoglycoside to attain a peak concentration of at least 4 mg/l of aminoglycoside and thereafter maintaining the aminoglycoside at a concentration of up to 4 mg/l for at least 1 hour. Compositions comprising an antibacterial agent and an aminoglycoside for efficacious treatment of bacterial infection are also provided.Type: GrantFiled: July 23, 2002Date of Patent: February 22, 2005Assignee: Pharmacy and Therapeutic Advisory Consultancy Pty LTDInventor: Allan Joseph McLean
-
Patent number: 6818625Abstract: The present invention relates to a method for increasing survival rate of cells in animal cell culture under hypoxia condition by adding antibiotics to the culture media. The method of present invention comprises a step of culturing animal cells in culture media containing antibacterial agent of quinolones, quinones, aminoglycosides or chloramphenicol at the concentration range of 0.1 to 1000 &mgr;g/ml. The invented method can be practically applied for high-density animal cell culture to produce recombinant proteins or cultured cells.Type: GrantFiled: July 12, 2002Date of Patent: November 16, 2004Assignee: Hypoxi Co., Ltd.Inventors: Jongwon Lee, Kyu-Won Kim, Mee-Jung Han, Moo Hwan Cho, Yang-Il Kim
-
Publication number: 20040186064Abstract: The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium Pseudomonas aeruginosa associated to lung diseases such as cystic fibrosis.Type: ApplicationFiled: April 28, 2004Publication date: September 23, 2004Inventors: Chiara Malvolti, Raffaella Garzia
-
Publication number: 20040176312Abstract: The treatment of ungual and subungual diseases is disclosed.Type: ApplicationFiled: February 2, 2004Publication date: September 9, 2004Inventor: Scott H. Gillis
-
Publication number: 20040171561Abstract: Methods of using a topical composition comprising a storage-stable mixture of a benzoyl peroxide dispersion and clindamycin or pharmaceutically acceptable salts or esters thereof for treating rosacea. These methods also contemplate the reduction or elimination of Demodex folliculorum organisms from affected skin areas, thereby reducing clinical signs of rosacea potentially due to allergic and vasomotor responses of the body to the organism in susceptible persons.Type: ApplicationFiled: March 4, 2004Publication date: September 2, 2004Inventor: Karl F. Popp
-
Publication number: 20040151671Abstract: The present invention provides various pharmaceutically active topical delivery compositions. In particular, compositions of the present invention are present in a pressurized container comprising a quick-breaking alcoholic foaming agent, such that when the composition is released, i.e., dispensed, from the pressurized container, a quick-breaking temperature sensitive foam is formed. In addition, the present invention provides various aspects related to such compositions, including methods for modulating a foam characteristic, methods for improving the shelf-life of a pharmaceutically active compound, methods for the percutaneous treatment of various diseases, infections, and illnesses, and methods for evaluating foam characteristics.Type: ApplicationFiled: January 23, 2004Publication date: August 5, 2004Applicant: Connetics Australia Pty Ltd.Inventors: Albert Zorko Abram, Barry Thomas Hunt
-
Publication number: 20040110694Abstract: A novel solid pharmaceutical dispersion that improves the bioavailability of poorly water soluble drugs is produced by combining the drug with a polymer carrier such as polyvinylpyrrolidone. The drug is combined with the carrier without the need for using organic solvents or melting temperatures (fusion) through the use of a transition compound such as polyethylene glycol which partially solubilizes the drug and/or plasticizes the polymer.Type: ApplicationFiled: December 3, 2003Publication date: June 10, 2004Inventors: Isaac Ghebre-Sellassie, Robert Reisch, Riten Parikh, Mahdi B. Fawzi, Russell U. Nesbitt
-
Publication number: 20040081684Abstract: The present invention provides a topical drug delivery system which comprises: a therapeutically effective amount of an antifungal agent; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and a volatile liquid. The invention also provides a method for administering at least one systemic acting antifungal agent to an animal which comprises applying an effective amount of the antifungal agent in the form of the drug delivery system of the present invention.Type: ApplicationFiled: August 20, 2003Publication date: April 29, 2004Applicant: Monash UniversityInventors: Nora Yat Knork Chew, Barry Leonard Reed, Timothy Matthias Morgan, Barrie Charles Finnin
-
Publication number: 20040077562Abstract: The invention consists of a stable preparation of a combination drug, comprising of an anti-inflammatory agent and an anti-infective agent. The anti-inflammatory agent in this invention is a corticosteroid, and the anti-infective agent is a derivative of quinolone, amino-glycoside or their pharmaceutically acceptable salts. The combination drug essentially comprises of i) an anti-inflammatory agent which is a corticosteroid, ii) an anti-infective agent selected from the group comprising of derivatives of quinolone, aminoglycoside and their pharmaceutically acceptable salts; iii) a complexation enhancing polymer; iv) a solubiliser exhibiting an inclusion phenomenon, along with pharmaceutically acceptable excipients with a suitable carrier system.Type: ApplicationFiled: October 20, 2003Publication date: April 22, 2004Inventors: Mohan A. Chandavarkar, Nandan M. Chandavarkar, Mainde Chandrashekhar
-
Publication number: 20040072201Abstract: The invention provides screening methods for the identification of compounds that inhibit nonstop degradation of mRNA, including compounds that inhibit the exosome. The invention further provides methods of treatment for genetic disorders caused by premature termination codons.Type: ApplicationFiled: April 16, 2003Publication date: April 15, 2004Inventors: Harry C. Dietz, Pamela A. Frischmeyer, Roy Robert Parker, Ambrosius Theodorus Cornelis Van Hoof
-
Publication number: 20040067253Abstract: The invention relates to hardly soluble antiphlogistic salts and antiphlogistic-antibiotic pharmaceutical preparations and their use. The hardly water soluble antiphlogistic antibiotics salts have as their cationic component one of the antibiotics gentamicin, clindamycin, neomycin, streptomycin, tetracycline, doxicyline, oxytetracycline and rolitetracycline and as their anionic component one of the antiphlogistics ibuprofen, naproxen, indomethacin, dexamethasone-21-phosphate, dexamethasone-21-sulfate, triamcinolone-21-phosphate and triamcinolone-21-sulfate. The antiphlogistic antibiotics salts are used in pharmaceutical preparations as controlled-release antibiotic/antibiotics drugs.Type: ApplicationFiled: June 20, 2003Publication date: April 8, 2004Applicant: Heraeus Kulzer GmbH & Co. KGInventors: Sebastian Vogt, Matthias Schnabelrauch, Klaus-Dieter Kuhn
-
Patent number: 6716822Abstract: The present invention relates to a therapeutic agent for ischemia which inhibits apoptosis under ischemic condition. The therapeutic agent of the present invention comprises antibacterial agents of quinolones, quinones, aminoglycosides or chloramphenicol as an active ingredient. Since the invented therapeutic agent improved the viability of cells under hypoxic and hypoglycemic condition, it can be clinically for ischemic diseases such as applied as a potential drug for ischemia-associated infarction and cerebral infarction.Type: GrantFiled: July 12, 2002Date of Patent: April 6, 2004Assignee: Hypoxi Co., Ltd.Inventors: Jongwon Lee, Kyu-Won Kim, Jong-Kyun Lee, Sang Jong Lee
-
Publication number: 20040058880Abstract: This invention relates to novel aminoglycoside compounds having antibacterial and anti-infective activity and to pharmaceutical compositions, methods of making and methods of treatment employing the same.Type: ApplicationFiled: June 26, 2003Publication date: March 25, 2004Inventors: Chang-Hsing Liang, Kenneth Marby, David Rabuka, Alex Romero, Paul W. M. Sgarbi, Steven J. Sucheck, Youe-Kong Shue, Sulan Yao
-
Patent number: 6706290Abstract: Nanobacteria contribute to pathological calcification in the human and animal body, including diseases such as kidney stones, salivary gland stones, dental pulp stones and atherosclerosis. The present invention provides methods for sterilizing articles contaminated with nanobacteria. The present invention also provides methods of treating patients infected with nanobacteria. In particular, the present invention provides a method for preventing the recurrence of kidney stones in a patient that has suffered from kidney stones, comprising administration of an antibiotic, a bisphosphonate, or a calcium chelator, either alone or in combination, in an amount effective to inhibit or prevent the growth and development of nanobacteria.Type: GrantFiled: July 2, 1999Date of Patent: March 16, 2004Inventors: Olvai E. Kajander, Neva Ciftcioglu
-
Publication number: 20040029783Abstract: A method for treating inhalation anthrax is disclosed. The inventive method comprises the use of 2,3-alkylcarbonyloxybenzoic acid and salts thereof in the prevention and treatment of lung damage caused by Bacillus anthracis and toxins produced by the bacterium. The 2,3-alkylcarbonyloxybenzoic acid may be used alone or in combination with other therapeutic agents such as antibiotics.Type: ApplicationFiled: October 31, 2002Publication date: February 12, 2004Inventor: Karen J. Stec
-
Publication number: 20040022831Abstract: The present invention relates to a composition comprising a) at least one antimycotic agent and b) at least one film forming agent wherein component b) is a derivative of chitosan selected from hydroxyalkylchitosans and carboxyalkylchitosans and its use as a nail varnish. The present invention is further directed to the use of a water soluble film forming agent selected from hydroxyalkylchitosans and carboxyalkylchitosans as an additive in a nail varnish.Type: ApplicationFiled: June 23, 2003Publication date: February 5, 2004Inventor: Federico Mailland